Suppr超能文献

宫颈癌前病变管理中“即诊即治”策略的过度治疗与成本效益

Overtreatment and Cost-Effectiveness of the See-and-Treat Strategy for Managing Cervical Precancer.

作者信息

Nghiem Van T, Davies Kalatu R, Beck J Robert, Follen Michele, Cantor Scott B

机构信息

Center for Health Promotion and Prevention Research, The University of Texas School of Public Health, Houston, Texas. Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, Texas.

出版信息

Cancer Epidemiol Biomarkers Prev. 2016 May;25(5):807-14. doi: 10.1158/1055-9965.EPI-15-1044. Epub 2016 Feb 29.

Abstract

BACKGROUND

See-and-treat using loop electrosurgical excision procedure (LEEP) has been recommended as an alternative in managing high-grade cervical squamous intraepithelial lesions, but existing literature lacks evidence of the strategy's cost-effectiveness. We evaluated the overtreatment and cost-effectiveness of the see-and-treat strategy compared with usual care.

METHODS

We modeled a hypothetical cohort of 40-year-old females who had not been screened for cervical cancer and followed them through their lifetimes using a Markov model. From a U.S. health-system perspective, the analysis was conducted in 2012 dollars and measured effectiveness in quality-adjusted life-years (QALY). We estimated incremental cost-effectiveness ratios (ICER) using a willingness-to-pay threshold of $50,000/QALY. The robustness of the see-and-treat strategy's cost-effectiveness and its overtreatment rates were further examined in various sensitivity analyses.

RESULTS

In the base-case, the see-and-treat strategy yielded an ICER of $70,774/QALY compared with usual care. For most scenarios in the deterministic sensitivity analysis, this strategy had ICERs larger than $50,000/QALY, and its cost-effectiveness was sensitive to the disutility of LEEP treatment and biopsy-directed treatment adherence under usual care. Probabilistic sensitivity analysis showed that the see-and-treat strategy had a 50.1% chance to be cost-effective. It had an average overtreatment rate of 7.1% and a 78.8% chance to have its overtreatment rate lower than the 10% threshold.

CONCLUSION

The see-and-treat strategy induced an acceptable overtreatment rate. Its cost-effectiveness, compared with usual care, was indiscriminating at the chosen willingness-to-pay threshold but much improved when the threshold increased.

IMPACT

The see-and-treat strategy was reasonable for particular settings, that is, those with low treatment adherence. Cancer Epidemiol Biomarkers Prev; 25(5); 807-14. ©2016 AACR.

摘要

背景

采用环形电切术(LEEP)进行即诊即治被推荐为高级别宫颈鳞状上皮内病变管理的一种替代方法,但现有文献缺乏该策略成本效益的证据。我们评估了即诊即治策略与常规治疗相比的过度治疗情况及成本效益。

方法

我们构建了一个未进行过宫颈癌筛查的40岁女性的假设队列,并使用马尔可夫模型对她们进行终生随访。从美国卫生系统的角度,分析以2012年美元进行,并以质量调整生命年(QALY)衡量有效性。我们使用每QALY支付意愿阈值50,000美元来估计增量成本效益比(ICER)。在即诊即治策略成本效益及其过度治疗率的稳健性在各种敏感性分析中进一步进行了检验。

结果

在基础病例中,与常规治疗相比,即诊即治策略产生的ICER为每QALY 70,774美元。在确定性敏感性分析的大多数情况下,该策略的ICER大于每QALY 50,000美元,并且其成本效益对LEEP治疗的负效用和常规治疗下活检导向治疗的依从性敏感。概率敏感性分析表明,即诊即治策略具有50.1%的成本效益机会。其平均过度治疗率为7.1%,并且有78.8%的机会使其过度治疗率低于10%的阈值。

结论

即诊即治策略导致了可接受的过度治疗率。与常规治疗相比,其成本效益在所选择的支付意愿阈值下并无差异,但当阈值增加时则有很大改善。

影响

即诊即治策略在特定环境中是合理的,即那些治疗依从性低的环境。《癌症流行病学、生物标志物与预防》;25(5);807 - 14。©2016美国癌症研究协会。

相似文献

1
Overtreatment and Cost-Effectiveness of the See-and-Treat Strategy for Managing Cervical Precancer.
Cancer Epidemiol Biomarkers Prev. 2016 May;25(5):807-14. doi: 10.1158/1055-9965.EPI-15-1044. Epub 2016 Feb 29.
2
Should endocervical curettage routinely be performed at the time of colposcopy? A cost-effectiveness analysis.
J Low Genit Tract Dis. 2014 Apr;18(2):101-8. doi: 10.1097/LGT.0b013e3182a0b572.
3
Inefficiencies and High-Value Improvements in U.S. Cervical Cancer Screening Practice: A Cost-Effectiveness Analysis.
Ann Intern Med. 2015 Oct 20;163(8):589-97. doi: 10.7326/M15-0420. Epub 2015 Sep 29.
4
Treatment strategies for stage IB cervical cancer: A cost-effectiveness analysis from Korean, Canadian and U.S. perspectives.
Gynecol Oncol. 2016 Jan;140(1):83-9. doi: 10.1016/j.ygyno.2015.11.007. Epub 2015 Nov 6.
5
Cost-effectiveness of para-aortic lymphadenectomy before chemoradiotherapy in locally advanced cervical cancer.
J Gynecol Oncol. 2015 Jul;26(3):171-8. doi: 10.3802/jgo.2015.26.3.171. Epub 2015 Apr 17.
6
Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.
Vaccine. 2013 Aug 20;31(37):3962-71. doi: 10.1016/j.vaccine.2013.06.008. Epub 2013 Jun 15.
9
Factors Related to Overtreatment in the See-and-Treat Approach: A Retrospective Multicentric Observational Study.
J Low Genit Tract Dis. 2019 Apr;23(2):129-132. doi: 10.1097/LGT.0000000000000455.

本文引用的文献

1
An alternative approach for estimating the accuracy of colposcopy in detecting cervical precancer.
PLoS One. 2015 May 11;10(5):e0126573. doi: 10.1371/journal.pone.0126573. eCollection 2015.
2
Economic evaluation of DNA ploidy analysis vs liquid-based cytology for cervical screening.
Br J Cancer. 2015 Jun 9;112(12):1951-7. doi: 10.1038/bjc.2015.95. Epub 2015 Apr 28.
4
See-and-treat approach to cervical intraepithelial lesions in HRH Princess Maha Chakri Sirindhorn Medical Center.
Asian Pac J Cancer Prev. 2014;15(8):3483-6. doi: 10.7314/apjcp.2014.15.8.3483.
5
See-and-treat management of high-grade squamous intraepithelial lesions in a resource-constrained African setting.
Int J Gynaecol Obstet. 2014 Mar;124(3):204-6. doi: 10.1016/j.ijgo.2013.07.040. Epub 2013 Dec 4.
6
Practice Bulletin No. 140: management of abnormal cervical cancer screening test results and cervical cancer precursors.
Obstet Gynecol. 2013 Dec;122(6):1338-67. doi: 10.1097/01.AOG.0000438960.31355.9e.
7
In reply.
Obstet Gynecol. 2013 Dec;122(6):1304-5. doi: 10.1097/AOG.0000000000000031.
9
Overtreatment in a see-and-treat approach to cervical intraepithelial lesions.
Obstet Gynecol. 2013 Jun;121(6):1209-1216. doi: 10.1097/AOG.0b013e318293ab22.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验